

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel.: (91-22) 4324 4324  
Fax: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



December 31, 2024

**National Stock Exchange of India Limited**  
**Script Symbol: SUNPHARMA**

**BSE Limited**  
**Script Code: 524715**

**Subject - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Sale of Subsidiary**

---

This is to inform that Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or affiliates referred to as “Sun Pharma”) has entered into an agreement with Zaza Industrial Holdings K.K, Japan, under which Sun Pharma has agreed to sell 100% shares held in Sun Pharma Japan Technical Operations Limited, a step-down subsidiary of the Company (through its subsidiary, Sun Pharma Japan Limited). Consequently, Sun Pharma Japan Technical Operations Limited shall cease to be a subsidiary of the Company.

**Annexure A**, enclosed herewith, provides the particulars of the disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Part A of Schedule III.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary and Compliance Officer**  
ICSI Membership No.: A23983

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
 Western Express Highway, Goregaon (E),  
 Mumbai – 400 063, Maharashtra, INDIA.  
 Tel.: (91-22) 4324 4324  
 Fax: (91-22) 4324 4343  
 Website: [www.sunpharma.com](http://www.sunpharma.com)  
 Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
 CIN: L24230GJ1993PLC019050

**Annexure A**
**Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

<b>Sl. No.</b>	<b>Particulars</b>	<b>Information</b>
a)	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	Turnover of Sun Pharma Japan Technical Operations Limited is less than 0.5% of Sun Pharma's consolidated turnover for FY 2023-24.  Sun Pharma Japan Technical Operations Limited operates a plant in Saitama, Japan, which manufactures products for Sun Pharma Japan Limited. As part of the sale agreement, the plant is contracted to supply products to Sun Pharma until May 2026.
b)	Date on which the agreement for sale has been entered into	December 31, 2024
c)	The expected date of completion of sale/disposal;	January 31, 2025
d)	Consideration received from such sale/disposal	JPY 1 (Japanese Yen One only)
e)	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof	Zaza Industrial Holdings K.K., a company incorporated under the laws of Japan whose registered office is at Toranomon Hills Edomizaka Terrace #1101, 9-1, Toranomon 2-chome, Minato-ku, Tokyo, 105-0001, Japan.  It does not belong to Promoter or Promoter Group of Sun Pharma.
f)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	No
g)	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	Not Applicable
h)	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	Not Applicable